BDH FY26 Net Profit Rises 16.6% to ₹1081.38 Lakh
BDH Industries Limited reported a 16.6% rise in FY26 net profit to ₹1081.38 lakh, with revenue from operations growing to ₹9595.46 lakh. The board recommended a ₹5 per share dividend for the fiscal year 2025-26 and appointed auditors for the upcoming year.
*this image is generated using AI for illustrative purposes only.
BDH Industries Limited has announced its audited standalone financial results for the fourth quarter and fiscal year ended March 31, 2026. The company reported a net profit of ₹1081.38 lakh for the full year, marking a 16.6% increase over the ₹927.33 lakh recorded in the previous fiscal year. Revenue from operations for FY26 surged to ₹9595.46 lakh from ₹6650.83 lakh in FY25, driven by strong performance across its pharmaceutical and renewable energy segments.
For the quarter ended March 31, 2026, the company posted a net profit of ₹287.91 lakh, compared to ₹248.87 lakh in the corresponding quarter of the previous year. Quarterly revenue from operations increased to ₹2903.23 lakh from ₹1782.16 lakh in the same period last year. The board has recommended a dividend of ₹5 per equity share of face value ₹10 each for the fiscal year 2025-26, pending approval by shareholders at the 36th Annual General Meeting scheduled for August 14, 2026.
Financial Performance Overview
The company's total income for the year rose to ₹9819.84 lakh from ₹6834.71 lakh in the prior year. Profit before tax for FY26 stood at ₹1519.39 lakh, an improvement from ₹1246.71 lakh in FY25. Earnings per share (EPS) for the year increased to ₹18.78 from ₹16.11 in the previous year. The statutory auditors, M/s. CLB & Associates, issued an unmodified opinion on the audited standalone financial results.
Segment-wise Results
Operations are primarily divided into Pharmaceuticals and Renewable Energy segments. The Pharmaceutical segment contributed the majority of the revenue, reporting ₹9509.31 lakh for the year ended March 31, 2026, while the Renewable Energy segment contributed ₹86.15 lakh. The total assets of the company as of March 31, 2026, stood at ₹9908.51 lakh, compared to ₹8693.81 lakh in the previous year.
| Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 9595.46 | 6650.83 |
| Total Income | 9819.84 | 6834.71 |
| Total Expenses | 8300.45 | 5588.00 |
| Profit Before Tax | 1519.39 | 1246.71 |
| Net Profit | 1081.38 | 927.33 |
| Earnings Per Share (₹) | 18.78 | 16.11 |
Corporate Governance Updates
In addition to the financial results, the board appointed Chhajed Kedia & Associates as Internal Auditors and Krishna S. & Associates as Cost Auditors for FY 2026-27. The board also recommended the appointment of Ms. Karthika Nair as Director retiring by rotation, subject to shareholder approval. The 36th Annual General Meeting will be held via Video Conferencing on August 14, 2026.
Historical Stock Returns for BDH Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.62% | -3.88% | -5.21% | -7.82% | +44.56% | +260.81% |
Given BDH Industries' 44% revenue surge in FY26, what specific growth strategies or new contracts are driving the pharmaceutical segment's expansion, and can this trajectory be sustained into FY27?
With the Renewable Energy segment contributing only ₹86.15 lakh compared to ₹9509.31 lakh from Pharmaceuticals, does the company plan to significantly scale up its renewable energy operations or divest from that segment?
How might potential regulatory changes in India's pharmaceutical sector or increased competition from generic drug manufacturers impact BDH Industries' profit margins in the coming fiscal year?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
